Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 92,626 shares at $4.84 ($446K) on 2022-03-30, disclosed to the SEC on 2022-04-01.
Open-market sale of $446k ROIV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.74 | 25,254 | $120K | 26.9% |
| 2 | $4.84 | 33,686 | $163K | 36.6% |
| 3 | $4.84 | 33,686 | $163K | 36.6% |
| Total | $4.81 avg | 92,626 | $446K | 100% |
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |